Leerink Partners Reiterates Outperform Rating on Benitec BioPharma (BNTC)

October 14, 2024 6:05 AM UTC Send to a Friend
Leerink Partners analyst Mani Foroohar reiterated an Outperform rating and $13.00 price target on Benitec BioPharma (NASDAQ: BNTC).The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login